Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin affects H...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadini, Gian Paolo, Bonora, Benedetta Maria, Zatti, Giancarlo, Vitturi, Nicola, Iori, Elisabetta, Marescotti, Maria Cristina, Albiero, Mattia, Avogaro, Angelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379610/
https://www.ncbi.nlm.nih.gov/pubmed/28376855
http://dx.doi.org/10.1186/s12933-017-0529-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379610/
https://www.ncbi.nlm.nih.gov/pubmed/28376855
http://dx.doi.org/10.1186/s12933-017-0529-3

Ejemplares similares